Phytoplant Research S.L. Unveils Innovative Industrial Chain for the Production of Cannabigerol (CBG) at CANN10

Phytoplant Research S.L.’s latest breakthrough makes the production of purified CBG from CBG-rich Cannabis plants at half the current cost a reality.

Cordoba, Spain – June 05, 2017 – Dr. Xavier Nadal, Director of the Extraction Department of Phytoplant Research S.L., presented the Development of the Industrial Chain for the Production of Cannabigerol (CBG): from Plant to Pure Compound at Cann10, the 2nd International Medical Cannabis Conference held on June 4-6, 2017, in Tel Aviv, Israel.

The presentation also marks the public announcement of the success of Phytoplant Research S.L in developing the most productive CBG-rich cannabis plants in the world.

“The 20-minute presentation by Dr. Xavier Nadal today at Cann10 in Tel Aviv, Israel is actually the summary of a 4-year effort by our team to both improve the productivity of CBG in our plant varieties and discover efficient purification methods. We are very proud of the outcome and really hope that this interesting molecule plays an important role in healthcare in the future, now that it can become more accessible and easy to produce” said Stefan Martin Meyer, CEO of Phytoplant Research S.L.

The company also holds a groundbreaking US patent for the purification and scaling up of the production of CBG easily and cost effectively. Their patented technique cuts the production costs of CBG by at least half than when using a chromatographic column.

“The new patented method is the first ever that purifies CBG without the use of chromatographic techniques. It permits scaling up the production of pure CBG using non-expensive equipment, cutting down the use of stationary phases and the use of different solvents. The result is a more efficient purification process that is cost effective and environmentally friendly,” said Dr. Nadal.

The development of this technique for the industrial production of CBG has far reaching implications considering the immense medicinal potential of this bioactive component of cannabis. The patent discloses methods of purifying one or more cannabinoids from a plant material, purified cannabinoids and pharmaceutical compositions comprising one or more cannabinoids produced using it. The methods and uses for treating a disease or condition employing such purified cannabinoids and pharmaceutical compositions are further investigated.

Media Contact:

Name: Stefan Martin Meyer, CEO

Phone: (0034) 957 10 16 29